Experience in Multiple Therapeutic Areas

CNS
Alzheimer’s Disease and other Dementias:
Design and execution of clinical programs (Phase I-IV) and regulatory submissions in all stages of Alzheimer’s disease from Mild Cognitive Impairment through severe AD including studies designed to show disease modification.  Clinical programs in Vascular Dementia, Cadasil and Parkinson’s Dementia. Compunds included cholinesterase inhibitors, MAO B inhibitor and a gamma secretase inhibitor.  
Seizure Disorders:
Phase I-III programs for adjunctive therapy for seizure disorders in adult and pediatric patients including partial and generalized seizures as well as Lennox-Gastaut Syndrome.
Parkinson’s Disease:
Phase II and Phase III program for adjunctive therapy using an AMPA antagonist
Other CNS: Programs for migraine prophylaxis, treatment of neuropathic pain, multiple sclerosis

Anti-Infectives and Sepsis
Sepsis:
Phase I- III for Toll 4 receptor antagonist for treatment of Sepsis.
Antibacterials:
Phase III and FDA advisory committee defense of telithromycin
Clinical development, dossier submission and advisory committee defense of first topical quinolone for treatment of otitis media and externa
Phase III/IV development of pipercillin/tazobactam

Other:
Development program for a novel imidazole
Investigator for early nucleoside anti-retroviral agents

Oncology

Both cytotoxic and kinase based therapies in monotherapy and combination.  Phase I/II programs in multiple indications and Phase III programs in Breast cancer

Gastroenterology

Phase I-IV programs for proton pump inhibitors for treatment and maintenance therapy in erosive and non-erosive GERD, H. pylori infection.  Also directed a program for conversion to OTC.

Other

Oversight of a variety of early programs in such areas as diabetes (ppar antagonist), psoriasis, par 1,3 antagonist for cardiovascular disease etc.